Selina M Luger

List of Publications by Citations

98 papers	4,615 citations	24 h-index	67 g-index
101 ext. papers	5,541 ext. citations	5.2 avg, IF	4.9 L-index

#	Paper	IF	Citations
98	Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. *New England Journal of Medicine*, **2012**, 366, 1079-89	59.2	1378
97	Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. *Blood*, **2001**, 98, 2301-7	2.2	631
96	In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). *Blood*, **2008**, 111, 1827-33	2.2	590
95	High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. *Journal of Clinical Oncology*, **2017**, 35, 394-401	2.2	227
94	Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. *Nature Medicine*, **2016**, 22, 792-9	50.5	217
93	A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. *Blood*, **2019**, 133, 1548-1559	2.2	178
92	Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia. *Cancer Discovery*, **2019**, 9, 1050-1063	24.4	148
91	Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia. *Cancer Cell*, **2015**, 28, 343-56	24.3	114
90	A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. *Blood*, **2015**, 125, 680-6	2.2	84
89	Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. *Blood*, **2016**, 127, 1551-8	2.2	81
88	Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. *Journal of Clinical Oncology*, **2020**, 38, 415-422	2.2	80
87	Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008. *Journal of Clinical Oncology*, **2016**, 34, 3544-3553	2.2	65
86	Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Review. *JAMA Oncology*, **2018**, 4, 725-734	13.4	64
85	How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. *Blood*, **2015**, 126, 589-96	2.2	48
84	Expression of tumor-suppressor genes interferon regulatory factor 1 and death-associated protein kinase in primitive acute myelogenous leukemia cells. *Blood*, **2001**, 97, 2177-9	2.2	47
83	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. *Lancet Haematology,the*, **2020**, 7, e601-e612	14.6	41
82	DNMT3A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia. *Clinical Cancer Research*, **2015**, 21, 1614-20	12.9	40

81	Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning. *Biology of Blood and Marrow Transplantation*, **2014**, 20, 1758-66	4.7	39
80	Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients. *Clinical Infectious Diseases*, **2019**, 68, 2003-2009	11.6	39
79	High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning. *Journal of Clinical Oncology*, **2015**, 33, 2392-8	2.2	38
78	Treating the elderly patient with acute myelogenous leukemia. *Hematology American Society of Hematology Education Program*, **2010**, 2010, 62-9	3.1	33
77	Relapsed T Cell ALL: Current Approaches and New Directions. *Current Hematologic Malignancy Reports*, **2019**, 14, 83-93	4.4	31
76	Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 248-257	4.7	27
75	Clinical Utility of Next-Generation Sequencing for Oncogenic Mutations in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 1961-1967	4.7	25
74	Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract. *Bone Marrow Transplantation*, **2019**, 54, 212-217	4.4	21
73	Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. *Leukemia*, **2020**, 34, 3149-3160	10.7	19
72	Soluble interleukin-2 receptor concentration as a biochemical indicator for acute graft-versus-host disease after allogeneic bone marrow transplantation. *Journal of Hematotherapy and Stem Cell Research*, **2000**, 9, 393-400		19
71	A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease. *American Journal of Hematology*, **2019**, 94, 111-117	7.1	19
70	Does Imatinib Change the Outcome in Philapdelphia Chromosome Positive Acute Lymphoblastic Leukaemia in Adults? Data from the UKALLXII/ECOG2993 Study.. *Blood*, **2007**, 110, 8-8	2.2	18
69	Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 515-521	4.7	16
68	Minimal Residual Disease in Acute Myeloid Leukemia. *Current Treatment Options in Oncology*, **2017**, 18, 1	5.4	14
67	How can one optimize induction therapy in AML?. *Best Practice and Research in Clinical Haematology* , **2017**, 30, 301-305	4.2	14
66	A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia. *JCI Insight*, **2016**, 1,	9.9	14
65	Phase I/II Study of MGCD0103, an Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, in Combination with 5-Azacitidine in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML).. *Blood*, **2007**, 110, 444-444	2.2	13
64	Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T-cell acute lymphoblastic leukaemia and lymphoma. *British Journal of Haematology*, **2016**, 174, 332-4	4.5	11

63	Patterns of Venous Thromboembolism Prophylaxis During Treatment of Acute Leukemia: Results of a North American Web-Based Survey. *Clinical Lymphoma, Myeloma and Leukemia*, **2015**, 15, 766-770	2	11
62	Stem cell transplantation for metastatic breast cancer: analysis of tumor contamination. *Medical Oncology and Tumor Pharmacotherapy*, **1999**, 16, 279-88		10
61	Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. *Leukemia*, **2021**, 35, 2076-2085	10.7	10
60	A Modified Integrated Genetic Model for Risk Prediction in Younger Patients with Acute Myeloid Leukemia. *PLoS ONE*, **2016**, 11, e0153016	3.7	9
59	Symptomatic Heart Failure in Acute Leukemia Patients Treated With Anthracyclines. *JACC: CardioOncology*, **2019**, 1, 208-217	3.8	9
58	Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. *Blood Advances*, **2021**, 5, 504-512	7.8	9
57	Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. *Leukemia and Lymphoma*, **2020**, 61, 1220-1225	1.9	8
56	Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition. *Investigational New Drugs*, **2018**, 36, 657-666	4.3	8
55	Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin. *Journal of Clinical Oncology*, **2021**, 39, 1001-1009	2.2	8
54	Maintenance therapy in acute myeloid leukemia: What is the future?. *Seminars in Hematology*, **2019**, 56, 102-109	4	8
53	Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2021**, 19, 1079-1109	7.3	8
52	Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agents. *American Journal of Hematology*, **2020**, 95, 792-798	7.1	7
51	Acute promyelocytic leukemia presenting as a paraspinal mass. *Journal of Community and Supportive Oncology*, **2016**, 14, 126-9		6
50	Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment. *American Journal of Hematology*, **2016**, 91, 453-60	7.1	6
49	Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young Adults with Ph-Negative Acute Lymphoblastic Leukemia in First Complete Remission: Comparison of CALGB 10403 to Patients Reported to the CIBMTR. *Blood*, **2019**, 134, 261-261	2.2	5
48	A phase II study of mocetinostat, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in combination with 5-azacitidine in patients with myelodysplastic syndrome (MDS).. *Journal of Clinical Oncology*, **2013**, 31, 7116-7116	2.2	5
47	Venous thromboembolism following pegaspargase in adults receiving antithrombin supplementation. *Leukemia and Lymphoma*, **2020**, 61, 2200-2207	1.9	4
46	Two-dimensional speckle-tracking strain detects subclinical cardiotoxicity in older patients treated for acute myeloid leukemia. *Echocardiography*, **2019**, 36, 2033-2040	1.5	4

45	Gender differences in question-asking at the 2019 American Society of Hematology Annual Meeting. *Blood Advances*, **2020**, 4, 5473-5479	7.8	3
44	Combined B12 and folate deficiency presenting as an aggressive hematologic malignancy. *American Journal of Hematology*, **2015**, 90, 964-5	7.1	3
43	CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trials. *Blood Advances*, **2021**, 5, 4560-4568	7.8	3
42	Rapid fluorescence in situ hybridisation optimises induction therapy for acute myeloid leukaemia. *British Journal of Haematology*, **2020**, 191, 935-938	4.5	2
41	Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey. *Leukemia and Lymphoma*, **2020**, 61, 1455-1464	1.9	2
40	Acute myeloid leukemia: How to treat the fit patient over age 75?. *Best Practice and Research in Clinical Haematology*, **2019**, 32, 101105	4.2	2
39	Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a Large Web-Based Survey. *Blood*, **2018**, 132, 1825-1825	2.2	2
38	Phase I study of Debio1143 (AT406) in combination with daunorubicin (D) and cytarabine (C) in patients with poor-risk acute myeloid leukemia (AML).. *Journal of Clinical Oncology*, **2014**, 32, 7029-7029	2.2	2
37	Real World Survival Outcomes of CPX-351 Versus Venetoclax and Azacitadine for Initial Therapy in Adult Acute Myeloid Leukemia. *Blood*, **2021**, 138, 795-795	2.2	2
36	Unrelated donors are associated with improved relapse-free survival compared to related donors in patients with myelodysplastic syndrome undergoing reduced intensity allogeneic stem cell transplantation. *American Journal of Hematology*, **2016**, 91, 883-7	7.1	2
35	The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900). *Leukemia Research*, **2019**, 78, 29-33	2.7	1
34	Time to unrelated donor leukocyte infusion is longer, but incidence of GVHD and overall survival are similar for recipients of unrelated DLI compared to matched sibling DLI. *American Journal of Hematology*, **2016**, 91, 426-9	7.1	1
33	Post-Traumatic Stress Disorder (PTSD) Symptoms in Patients with Acute Myeloid Leukemia (AML). *Blood*, **2020**, 136, 44-45	2.2	1
32	R115777(tipifarnib) Improves Early Survival when Used As Maintenance Therapy for Elderly or Relapsed/Refractory Patients with Acute Myelogenous Leukemia in Remission. *Blood*, **2012**, 120, 676-676	2.2	1
31	Next-generation sequencing to identify mutations that may predict outcome after allogeneic stem cell transplantation for AML.. *Journal of Clinical Oncology*, **2014**, 32, 7043-7043	2.2	1
30	Systemic Inflammatory Response Syndrome (SIRS) as Predictor of Severe Sepsis (SS) in Hospitalized Patients (pts) with Hematologic Malignancies.. *Blood*, **2007**, 110, 633-633	2.2	1
29	Consolidation Therapy for Acute Myeloid Leukemia: Defining a Benchmark. *Journal of Clinical Oncology*, **2021**, 39, 870-875	2.2	1
28	Leucovorin Rescue After Methotrexate Graft-Versus-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment, and Hospital Length of Stay. *Transplantation and Cellular Therapy*, **2021**, 27, 431.e1-431.e8		1

27	Characterization of Pericarditis following Allogeneic Hematopoietic Cell Transplantation. *Transplantation and Cellular Therapy*, **2021**, 27, 934.e1-934.e6		1
26	Higher Donor Apheresis Blood Volumes Are Associated with Reduced Relapse Risk and Improved Survival in Reduced-Intensity Allogeneic Transplantations with Unrelated Donors. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 1203-1208	4.7	1
25	Dose intensity for induction in acute myeloid leukemia: what, when, and for whom?. *Haematologica*, **2021**, 106, 2544-2554	6.6	1
24	Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). *Cancer*, **2021**, 127, 4421-4431	6.4	1
23	Incidence and Predictors of Sars-Cov-2 Antibody Responses Following COVID-19 Vaccination in Allogeneic Stem Cell Transplant Recipients. *Blood*, **2021**, 138, 2888-2888	2.2	0
22	Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial. *Leukemia Research*, **2021**, 111, 106736	2.7	0
21	Posttraumatic stress disorder symptoms in patients with acute myeloid leukemia. *Cancer*, **2021**, 127, 2500-2506	6.4	0
20	Interpretative differences of combined cytogenetic and molecular profiling highlights differences between MRC and ELN classifications of AML. *Cancer Genetics*, **2021**, 256-257, 68-76	2.3	0
19	Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamide.. *Leukemia and Lymphoma*, **2022**, 1-9	1.9	0
18	Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia.. *Leukemia and Lymphoma*, **2022**, 1-6	1.9	0
17	Longitudinal targeted next-generation sequencing in a patient with acute myeloid leukaemia. *British Journal of Haematology*, **2019**, 186, 801	4.5	
16	Durable Remissions and Increased Overall Survival in AML Patients Deemed Unfit for Standard Intensive Chemotherapy Achieved with High-Dose BST-236 (Aspacytarabine) Induction and Consolidation. *Blood*, **2020**, 136, 9-10	2.2	
15	Patients with AML Who Achieve Long Term Complete Remission Do Not Have a Normal Life Expectancy When Compared to the General Population. Analysis of 3,012 Patients Enrolled on 9 Consecutive ECOG-ACRIN Trials. *Blood*, **2021**, 138, 690-690	2.2	
14	Timing between Rituximab and 90Y-Ibritumomab Tiuxetan in Pts with Non-Hodgkin§ Lymphoma Does Not Affect Clinical Outcomes.. *Blood*, **2006**, 108, 4735-4735	2.2	
13	A Predictive Model for Cytogenetic Risk Group in Elderly AML: The Penn Cytogenetic Surrogate Score (PCSS).. *Blood*, **2006**, 108, 4446-4446	2.2	
12	Predicting prognosis in patients with acute myeloid leukemia: The role of next-generation sequencing and mutational profiling.. *Journal of Clinical Oncology*, **2014**, 32, 7068-7068	2.2	
11	Delays in Start of Intensification Therapy Are Common for Adults with Acute Lymphoblastic Leukemia, and Are Associated with Decreased Survival in Patients Who Undergo Allogeneic Stem Cell Transplant (SCT). *Blood*, **2014**, 124, 208-208	2.2	
10	Time from Relapse to Donor Leukocyte Infusion in Allogeneic Stem Cell Transplantation Patients Is Longer for Recipients of Unrelated DLI Compared to Matched Sibling DLI, with Similar Incidence of Graft Versus Host Disease (GVHD) and Survival. *Blood*, **2014**, 124, 3946-3946	2.2	

9	A Clinical Measure of DNA Methylation Predicts Outcome in De Novo AML. *Blood*, **2015**, 126, 2591-2591	2.2
8	Initial Safety, Pharmacokinetic and Pharmacodynamic Data from a Phase I Clinical Trial of Systemic C-MYB Antisense Oligodeoxynucleotide in Subjects with Refractory Hematologic Malignancies. *Blood*, **2008**, 112, 4033-4033	2.2
7	Single-Cell Pharmacodynamic Monitoring of S6 Ribosomal Protein in AML Blasts During a Clinical Trial Combining the mTOR Inhibitor Sirolimus with Mitoxantrone, Etoposide, and Cytarabine Chemotherapy.. *Blood*, **2009**, 114, 413-413	2.2
6	A Feasibility Study of Rapamycin with Hyper-CVAD Chemotherapy in Adults with Acute Lymphoblastic Leukemia (ALL) and Other Aggressive Lymphoid Malignancies and Evaluation of mTOR Signaling Using Phosphoflow. *Blood*, **2011**, 118, 4245-4245	2.2
5	A randomized phase II study of sapacitabine in MDS refractory to hypomethylating agents.. *Journal of Clinical Oncology*, **2012**, 30, 6520-6520	2.2
4	Outcome of acute myeloid leukemia in patients with a history of autoimmune disease.. *Journal of Clinical Oncology*, **2012**, 30, 6579-6579	2.2
3	Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902. *Transfusion*, **2020**, 60, 1867-1872	2.9
2	Day 4 vs. day 12 G-CSF administration following reduced intensity peripheral blood allogeneic stem cell transplant.. *Journal of Oncology Pharmacy Practice*, **2022**, 10781552221080710	1.7
1	Pentosan polysulfate for the treatment of hemorrhagic cystitis after allogeneic hematopoietic cell transplant. *Journal of Oncology Pharmacy Practice*,107815522211052	1.7